Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe page now shows a 403 Forbidden error with a minimal header and a Home link. The previous study record content appears to be removed or hidden.SummaryDifference18%

- Check9 days agoChange DetectedA new page revision v3.7.0 is added and the previous revision v3.6.6 is removed, signaling an update to the page version.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision label was updated from v3.6.5 to v3.6.6, representing a maintenance update to the page's version identifier. It does not alter the study content or user-visible features.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision tag on the page has been updated from v3.6.4 to v3.6.5, indicating a new version of the ClinicalTrials.gov page. This reflects a minor backend update to the page rather than any change to the study details or enrollment information.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page's revision label was updated to v3.6.4. This indicates a minor content update without changing study details.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page's revision tag was updated from Revision: v3.6.2 to Revision: v3.6.3, indicating a newer release of the page. This is an internal version update and does not modify the study details or visible content.SummaryDifference0.1%

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.